Exploring the Role of Biosimilars in Optimizing Treatment of Retinal Diseases

Ranibizumab-nuna: Review of Clinical Trial Data

Neil Bressler, MD

Show Description +

Neil Bressler, MD, reviews the phase 3 clinical trial outcomes, as well as outcomes from a 52-week follow-up.

Posted: 4/14/2023

Keywords:

Biogen

•

biosimilars

•

Clinical Trials

•

ranibizumab-nuna

Up Next

Name: Ranibizumab-nuna: Review of Clinical Trial Data
Uploaded: 2023-04-14T21:08:58+00:00
Description: Neil Bressler, MD, reviews the phase 3 clinical trial outcomes, as well as outcomes from a 52-week follow-up.

A Deeper Look at Clinical Trial Outcomes

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

Adopting Bioimilars: Practical Considerations

David Brown, MD

Biosimilars: Health Economic Aspects

David Brown, MD

Biosimilars: Learning from Other Parts of Medicine

Diana Do, MD

What Does the Conversation Sound Like?

David Brown, MD

The Current Treatment Paradigm in nAMD

Diana Do, MD

Undertreatment of nAMD and Implications for LongTerm Vision

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

What Is a Biosimilar?

Peter Kaiser, MD

Biosimilars: Impact on Cost

Peter Kaiser, MD

Understanding Biosimilar Clinical Trials

Peter Kaiser, MD

Back to All Videos

Ranibizumab-nuna: Review of Clinical Trial Data

Neil Bressler, MD

Neil Bressler, MD, reviews the phase 3 clinical trial outcomes, as well as outcomes from a 52-week follow-up.

Posted: 4/14/2023

Keywords:

Biogen

•

biosimilars

•

Clinical Trials

•

ranibizumab-nuna

Resources

Biosimilars in Retinal Disease Management

View Resource

About Biogen

One of the world’s first global biotechnology companies, Biogen, was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Biogen is commercializing biosimilars and transforming the standard of care for patients in several areas of high unmet need.

Follow Biogen